Sofinnova crosses over

Why Sofinnova Partners has branched out with its first crossover fund

Sofinnova Partners raised its first crossover fund to attract international investors to late-stage EU biotechs, with the goal of bringing the best to the U.S. market.

On April 4, Sofinnova announced the close of Sofinnova Crossover I at €275 million ($340.5

Read the full 419 word article

How to gain access

Continue reading with a
two-week free trial.